Radiation and Nuclear Countermeasures Program (RNCP), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), US Department of Health and Human Services (HHS), Washington, DC, USA.
Chemical Medical Countermeasures (MCM) Program, Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), Washington, DC, USA.
Disaster Med Public Health Prep. 2024 Feb 22;18:e35. doi: 10.1017/dmp.2023.226.
Although chemical and radiological agents cause toxicity through different mechanisms, the multiorgan injuries caused by these threats share similarities that convene on the level of basic biological responses. This publication will discuss these areas of convergence and explore "multi-utility" approaches that could be leveraged to address common injury mechanisms underlying actions of chemical and radiological agents in a threat-agnostic manner. In addition, we will provide an overview of the current state of radiological and chemical threat research, discuss the US Government's efforts toward medical preparedness, and identify potential areas for collaboration geared toward enhancing preparedness and response against radiological and chemical threats. We also will discuss previous regulatory experience to provide insight on how to navigate regulatory paths for US Food and Drug Administration (FDA) approval/licensure/clearance for products addressing chemical or radiological/nuclear threats. This publication follows a 2022 trans-agency meeting titled, "Overlapping Science in Radiation and Sulfur Mustard Exposures of Skin and Lung: Consideration of Models, Mechanisms, Organ Systems, and Medical Countermeasures," sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). Discussions from this meeting explored the overlapping nature of radiation and chemical injury and spurred increased interest in how preparedness for one threat leads to preparedness for the other. Herein, subject matter experts from the NIAID and the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR), summarize the knowledge gained from recently funded biomedical research, as well as insights from the 2022 meeting. These topics include identification of common areas for collaboration, potential use of biomarkers of injury to identify injuries caused by both hazards, and common and widely available treatments that could treat damage caused by radiological or chemical threats.
尽管化学和放射性药剂通过不同的机制引起毒性,但这些威胁造成的多器官损伤具有相似之处,集中在基本生物学反应的层面上。本出版物将讨论这些趋同领域,并探讨“多用途”方法,这些方法可以利用这些方法以威胁无关的方式解决化学和放射性药剂作用下的共同损伤机制。此外,我们将概述放射性和化学威胁研究的现状,讨论美国政府在医疗准备方面的努力,并确定潜在的合作领域,以增强对放射性和化学威胁的准备和应对。我们还将讨论以前的监管经验,以提供有关如何为解决化学或放射性/核威胁的产品导航美国食品和药物管理局 (FDA) 批准/许可/清除监管途径的见解。本出版物遵循 2022 年一次跨机构会议的主题,即“皮肤和肺部辐射和硫芥暴露的重叠科学:考虑模型、机制、器官系统和医疗对策”,该会议由过敏和传染病研究所 (NIAID) 主办,该研究所是美国国立卫生研究院 (NIH) 的一部分。此次会议的讨论探讨了辐射和化学损伤的重叠性质,并促使人们更加关注为一种威胁做好准备如何为另一种威胁做好准备。在此,NIAID 和生物医学高级研究与发展管理局 (BARDA) 的主题专家(BARDA 是战略准备和应对管理局 (ASPR) 的一部分)总结了最近资助的生物医学研究中获得的知识,以及 2022 年会议的见解。这些主题包括确定合作的共同领域、潜在使用损伤生物标志物来识别这两种危险造成的损伤,以及常见且广泛可用的治疗方法可以治疗放射性或化学威胁造成的损伤。